Replies to post #199871 on Biotech Values

[DewDiligence]

Hard to say—the end result may be the same.

Correction to my previous post in this thread: LLY may decide to sue EGRX when the FDA accepts EGRX's RTU-Alimta NDA for review and EGRX notifies LLY of a Paragraph-IV challenge (not when the FDA approves the product for marketing).